(IDYA) IDEAYA Biosciences, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(IDYA) IDEAYA Biosciences, Inc. Complete Analysis Pack
See the Bigger Picture
This IDEAYA Biosciences, Inc. 4P's Marketing Mix Analysis explains the company’s products (drug candidates and collaboration services), how they’re priced, distributed, and promoted—helping you assess positioning and go-to-market strategy. This page shows a real preview/sample of the analysis; purchase the full version to get the complete, ready-to-use report.
Product
IDE397, Phase I
IDE397 is IDEAYA Biosciences, Inc.'s Phase I MAT2A inhibitor for MTAP-deleted solid tumors, built for biomarker-defined precision oncology. It is one of IDEAYA Biosciences, Inc.'s lead synthetic lethality programs, so the product strategy targets a genetically selected patient group rather than a broad cancer market. In the 4P mix, this supports a focused premium positioning, narrow clinical promotion, and a data-led development path.
IDE196, Phase I/II
IDE196 is IDEAYA Biosciences, Inc.'s Phase I/II PKC inhibitor for GNAQ or GNA11-mutant cancers, including metastatic uveal melanoma, a disease that spreads in about 50% of cases. The program fits IDEAYA's genetically selected model by matching treatment to the tumor driver. That focus helps concentrate clinical use in a defined, biomarker-led patient group.
PARG inhibitor, early-stage
IDEAYA’s early-stage PARG inhibitor adds another synthetic lethality program to its pipeline, aimed at tumors with specific genetic or molecular biomarkers. The asset is still pre-commercial, so the value is in pipeline breadth rather than current sales, and it sits alongside IDEAYA’s lead programs in MAT2A and PRMT5. That gives the Company more shots at biomarker-driven oncology readouts.
Pol Theta inhibitors, HRD
IDEAYA Biosciences, Inc. is advancing Pol Theta inhibitors for BRCA-mutant and other HRD cancers, aiming at a DNA-repair weakness that tumors depend on. This is a core precision-oncology bet, and HRD biology matters because roughly 20% to 25% of breast and ovarian cancers show homologous recombination repair defects.
The product fits a targeted model: find patients with repair-deficient tumors, then block Pol Theta to push cancer cells past repair failure. That can sharpen response in biomarker-defined groups and supports IDEAYA Biosciences, Inc.'s focus on high-value oncology niches.
- Targets BRCA-mutant and HRD tumors
- Uses synthetic lethality in DNA repair loss
- Core precision-oncology program
WRN inhibitors, MSI-H
IDEAYA Biosciences, Inc.'s WRN inhibitor program targets MSI-H tumors, a biomarker-defined group that makes up about 15% of colorectal cancers and about 4% to 5% of all solid tumors. That keeps the asset tightly selected, with a clear precision-oncology fit and less overlap with broader, non-biomarker assets. It also adds a second biomarker-led oncology shot alongside IDEAYA Biosciences, Inc.'s other targeted programs.
- MSI-H = distinct molecular niche
- About 15% of colorectal cancers
- About 4% to 5% of solid tumors
- Strengthens biomarker-driven portfolio
IDEAYA’s Precision Oncology Bet Targets Rare Genetic Niches
IDEAYA Biosciences, Inc. sells a biomarker-led oncology product mix: IDE397, IDE196, PARG, POLθ, and WRN. These are all early-stage and target small genetic niches, like MTAP loss, GNAQ/GNA11, HRD, MSI-H, and BRCA defects. That keeps the Product strategy narrow, premium, and data driven.
| Asset | Target | Fit |
|---|---|---|
| IDE397 | MTAP-deleted | Precision oncology |
What is included in the product
Detailed Word Document
A concise, company-specific 4P’s analysis of IDEAYA Biosciences, Inc.’s Product, Price, Place, and Promotion strategy.
Editable Excel File
Summarizes IDEAYA Biosciences’ 4Ps in a clean snapshot, helping teams quickly align on strategy and reduce analysis overload.
Reference Sources
Provides a concise, traceable bibliography of industry reports, clinical data, and regulatory filings to speed due diligence and validate IDEAYA Biosciences assumptions.
Place
South San Francisco HQ
IDEAYA Biosciences, Inc. is headquartered in South San Francisco, California, and that site anchors its corporate, research, and business functions. The address keeps Company Name in the center of the Bay Area biotech hub, where talent, labs, investors, and partners are close by. This location supports fast collaboration and helps Company Name stay close to the life science ecosystem it competes in.
Clinical trial sites
IDEAYA Biosciences, Inc. reaches patients through clinical trial sites, not retail pharmacies, so this "place" is the trial network itself. Investigational drugs are given only to biomarker-selected patients in ongoing studies, which makes site access the main route to market during development. As of 2025, IDEAYA’s pipeline was still anchored in clinical-stage programs, so site activation and enrollment speed directly shape uptake.
Pfizer supply network
IDEAYA Biosciences uses Pfizer Inc. as a supply and development partner for Phase I/II studies, which helps keep trial materials flowing across selected tumor types. That setup gives IDEAYA access to Pfizer's clinical and manufacturing reach, so the program is not limited to IDEAYA alone. In practice, Phase I/II execution lowers operational strain and supports faster site activation.
UK academic collaboration
IDEAYA Biosciences, Inc. works with Cancer Research UK and the University of Manchester on small-molecule inhibitor research, giving it access to 2 UK research anchors. The tie-up helps widen IDEAYA Biosciences, Inc.’s scientific reach beyond the US and into a leading European oncology hub.
- 2 UK partners
- Small-molecule inhibitor focus
- Expanded geographic footprint
- No disclosed deal value
GSK alliance channels
IDEAYA Biosciences, Inc. uses its GlaxoSmithKline plc alliance as a non-retail channel to speed research, development, and possible launch paths. The deal structure includes up to $730 million in milestones plus tiered royalties, so the channel can scale without building a full sales force. For biotech, that kind of partner-led route can widen reach fast.
- Non-retail partner channel
- Up to $730 million milestones
- Tiered royalties support reach
IDEAYA’s Clinical-Trial-First Strategy Powers Growth and GSK Upside
IDEAYA Biosciences, Inc. place is its South San Francisco base plus a biomarker-driven clinical trial network, since patients access its drugs only through study sites. In 2025, this model kept enrollment, site activation, and partner logistics as the main route to market. Its GSK alliance adds up to $730 million in milestones and tiered royalties.
| Place factor | 2025/2026 signal |
|---|---|
| HQ | South San Francisco, California |
| Route | Clinical trial sites |
| Partner reach | Up to $730M milestones |
What You See Is What You Get
IDEAYA Biosciences, Inc. Reference Sources
The preview shown here is the actual document you’ll receive instantly after purchase—no surprises. This IDEAYA Biosciences 4P's Marketing Mix Analysis is fully complete, editable, and ready to use, covering product positioning, pricing strategy, promotional channels, and placement considerations tailored to oncology-focused biotech markets.
Promotion
Clinical data readouts
IDEAYA uses clinical data readouts to market its pipeline, with each update showing progress in lead oncology programs and helping investors, oncologists, and researchers track proof of concept. These disclosures matter because clinical milestones can move value fast: for example, late-stage programs like Phase 2 and Phase 3 data are the main catalysts for biotech rerating. The readouts keep IDEAYA visible while it advances multiple precision-medicine assets.
Medical congress presentations
IDEAYA Biosciences, Inc. uses medical congress presentations to share clinical data, and that works well in oncology because specialist meetings like ASCO 2025 drew 40,000+ attendees. These talks help explain mechanism, efficacy, and biomarker rationale for assets such as darovasertib and IDE397. For a company with $353.8 million in cash and investments at 2025 year-end, this is a low-cost way to reach key prescribers and investors.
Investor communications
IDEAYA Biosciences uses earnings materials, SEC filings, and investor decks as a core promotion channel to show pipeline progress and funding strength. In Q1 2025, it reported about $1.1 billion in cash, cash equivalents, and marketable securities, which helps reassure capital markets on runway. These disclosures keep investors updated on trial milestones, clinical readouts, and capital needs.
Press releases
IDEAYA Biosciences uses press releases to announce partnerships, trial readouts, and program updates, giving the market fast, direct access to material news. In FY2025, this channel helped reinforce scientific credibility and keep investor attention on clinical milestones tied to its oncology pipeline. It is a low-cost way to widen reach fast.
- Partnership announcements
- Trial milestone updates
- Program progress and visibility
Biomarker-first messaging
IDEAYA Biosciences, Inc. uses biomarker-first promotion to sell precision oncology, not broad tumor claims. Its messaging targets MTAP, GNAQ, GNA11, BRCA, HRD, and MSI-H, with MTAP loss seen in about 10% to 15% of solid tumors, which helps the Company stand out in a crowded oncology market.
That focus fits synthetic lethality, where patient selection can raise response rates and sharpen trial design. In 2025, IDEAYA still used this niche positioning to signal a narrower but higher-value addressable market than general oncology plays.
- Targets biomarker-defined patients
- Uses MTAP as a key wedge
- Links promotion to synthetic lethality
- Helps reduce noisy competition
IDEAYA’s biomarker-led pipeline could turn every data readout into a catalyst
IDEAYA Biosciences, Inc. promotes its pipeline through clinical readouts, congress talks, press releases, and investor materials, so each data update can move attention fast. Its biomarker-first message, centered on MTAP and other precision-oncology targets, helps narrow the audience and sharpen trial interest.
| Promotion channel | 2025-2026 signal |
|---|---|
| Clinical readouts | Lead catalysts |
| Congress talks | ASCO 2025: 40,000+ attendees |
| Cash support | $353.8M year-end 2025 |
| Targeting | MTAP loss in 10%-15% of solid tumors |
Price
No list price
IDEAYA Biosciences, Inc.'s pipeline is still investigational, so there is no public list price today. As of the latest reported periods, the Company has no approved commercial product revenue, which keeps pricing undefined until approval and launch. Any eventual price will depend on trial outcomes, label scope, payer access, and launch timing.
Trial-stage economics
IDEAYA Biosciences, Inc. is still in the trial-stage, so pricing is pre-commercial: value comes from clinical progress, not product sales. In FY2025, that means funding through equity capital and collaboration support, with economics tied to milestone receipts, R&D spend, and pipeline readouts. That model stays binary: data drives valuation, not unit price.
Partner-funded supply
Pfizer covers clinical development and supply support in the IDEAYA Biosciences, Inc. partnership, so IDEAYA does not carry the full trial-supply bill on partnered studies. That lowers direct cash burn and fits IDEAYA Biosciences, Inc.'s capital-light economics. Partner-funded supply also helps protect R&D spend for 2025/2026 programs while Pfizer funds part of the work.
Future premium oncology pricing
If approved, IDEAYA Biosciences, Inc.'s biomarker-defined oncology drugs could support premium pricing, often above $100,000 per patient per year in the US for targeted cancer therapies. Narrow pools, such as the ~5,000 annual U.S. uveal melanoma cases, can raise perceived value, but final price will still hinge on label breadth, phase 3 data, and payer coverage.
- Biomarker fit supports premium value
- Narrow labels can lift willingness to pay
- Payer access can still cap net price
Reimbursement-driven launch
IDEAYA Biosciences, Inc. must price any oncology launch around payer coverage, not just list price. In the US, Medicare Part B often reimburses provider drugs at ASP plus 6%, but sequestration can trim that to about 4.3%, so access and net price can diverge fast. Payers will want proof of clinical benefit and health-economic value before broad coverage.
Coverage drives net price.
Clinical benefit supports access.
Value proof matters at launch.
IDEAYA’s Pricing Is Unset—But Premium Oncology Could Follow
IDEAYA Biosciences, Inc. has no commercial list price yet because its pipeline is still pre-approval, so 2025/2026 pricing remains undefined and tied to trial success, label size, and payer access. If launched, biomarker-led oncology drugs could support premium US pricing, often above $100,000 per patient a year. Coverage will matter more than sticker price, especially for narrow markets like the ~5,000 annual US uveal melanoma cases.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.